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during eight individual cognitive interviews. ConClusions: The mixed-methods 
approach provides valuable support in the development of a fit-for-purpose instru-
ment assessing impacts of cLBP. Upon testing this revised PAL-I in a second pilot 
quantitative study, the final measure will undergo formal validation including sen-
sitivity to change.
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objeCtives: 1) To identify orphan medicines indicated for lymphoproliferative dis-
orders approved by the European Medicines Agency (EMA); (2) To identify medicines 
for which a PRO evaluation was performed; (3) To list those with a PRO labeling claim, 
and (4) To identify reasons for not granting a PRO claim. Methods: The search 
was performed on the EMA website (06/21/2014). The products were browsed by 
type (i. e., orphan medicines). Products refused and withdrawn were excluded. The 
PROLabels database was searched for each product retrieved to identify any PRO 
claim in the label. Summary of Product characteristics (SMPc) and CHMP Assessment 
Reports (AR) were retrieved for each product and analyzed to find out about PRO 
evaluation reported in the AR and not reported in the label. Results: Thirteen 
orphan medicines indicated in lymphoproliferative disorders were identified, rep-
resenting three main indications: lymphomas (Hodgkin, systemic anaplastic large 
cell, T-cell lymphoblastic, mantle-cell), leukemias (chronic lymphocytic, hairy cell, 
acute lymphoblastic) and multiple myeloma. Only one product had a PRO claim: 
ofatumumab (resolution of constitutional symptoms). The label of another product 
(brentuximab vedotin) indicated “resolution of B symptoms.” However, there was 
no mention in the AR on how the symptoms were collected (patient or clinician). 
For one product (pomalidomide), a HRQL evaluation was mentioned in the AR, but 
not reported in the label. However, there was no information about this evaluation 
in the AR and the reader is left to wonder about the HRQL results and the reasons 
for not including them in the label. ConClusions: The percentage of PRO claims 
in orphan medicines (7.7%) is inferior to the percentage of PRO claims in all EMA 
products (26%). This is remarkably low considering the profound effect of lym-
phoproliferative disorders on patients’ life. Efforts should be made to improve the 
reporting of PRO data in the CHMP Assessment Reports.
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objeCtives: Phenylketonuria (PKU) is a rare genetic disorder impacting pheny-
lalanine (Phe) metabolism. Treatment involves a lifelong Phe restricted diet that 
is strict and socially demanding. Even when treated early and well, mild cogni-
tive abnormalities have been seen. PKU can affect quality of life in individuals 
and their families. The phenylketonuria–quality of life (PKU-QOL) questionnaires 
are the first PKU-specific QOL questionnaires ever developed. The study aimed to 
perform the psychometric validation of these questionnaires. Methods: An obser-
vational study was conducted in France, Germany, Italy, The Netherlands, Spain, 
Turkey and the UK to finalize and validate PKU-QoL questionnaires in individuals 
with treated PKU aged 9–11, 12–17 and ≥ 18 years, and in parents of individuals < 18 
years. Questionnaires were assessed for reliability (internal consistency, test–retest), 
concurrent validity (using three generic questionnaires adapted to the respondent: 
PedsQOL, SF-36 for adults and CHQ-PF28) and clinical validity (using PKU severity 
and overall assessment of patient health status). Results: In total, 559 participants 
(306 individuals, ages 9–45 years; 253 parents, ages 24–66 years) were included in the 
analysis. Return rate and quality of completion of the questionnaires were good, 
indicating good acceptability. Scores were defined to assess all relevant aspects of 
experiences: PKU symptoms, impact of PKU, dietary protein restriction and sup-
plementation. Reliability and validity were satisfactory overall for the adolescent, 
adult and parent PKU-QoL questionnaires, and slightly weaker but acceptable for 
the child version. ConClusions: The four PKU-QOL questionnaires are valid and 
reliable instruments for assessing the specific quality of life aspects that are affected 
in individuals with PKU of different age groups (children, adolescents and adults) 
and their parents, and are available in seven languages. They are very promising 
tools for focused evaluation of PKU impact on individuals and parents in different 
countries, and for monitoring the efficacy of therapeutic strategies.
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objeCtives: Dengue infection is a major cause of disease in tropical areas with 
an estimated 50 million infections occurring each year and more than 2.5 billion 
people being at risk of infections. The main objective of this study was to investigate 
relation between white blood cells and platelets during recovery phase in dengue 
hemorrhagic fever. Methods: A retrospective multi-center study was conducted 
on 1000 seropositive cases of dengue fever. Results: More prevalence has been 
observed in male 880 (88%) as compared to female 120 (12%). A rapid fall in white 
blood cells count (WBC) was observed in initial CBC reports at start of disease then 
observational study. It was conducted from September 2011 to December 2012 and 
included a total of 1,109 patients who were scheduled for lumbar spinal surgery 
from 44 spinal centers (both orthopaedic surgery and neurosurgeons). Patients were 
diagnosed of having NP if the Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS) pain scale criteria were ≥ 12 points. The patients were investigated 
to assess their pain severity using pain numeric rating scale (NRS) and quality 
of life using EuroQol (EQ)-5D at baseline, after 1 week and 3 months of the sur-
gery. Results: Among 1,109 patents, at baseline, NP was identified in 404 (36%) 
patients. After 1 week and 3 months of the surgery, NP was found in 8.6% and 
4.0% patients respectively. Among the 705 patients without NP preoperatively, the 
prevalence of de novo NP occurred in the 1 week and 3 months of post-surgery was 
3.1% and 2.3% respectively. At baseline, NP patients showed lower QoL compared 
with non-NP patients (0.49 vs 0.53 p< .001). However, NP patients improved more 
their QoL compared to non-NP patients after 3 months (0.86 vs 0.84 p=.029). Among 
the de novo NP patients at 3 months after surgery (n= 16), the pain severity was not 
improved after 1 week and 3 months of the surgery. ConClusions: In Korea, NP 
patients were suffered from severe pain and lower QoL than non-NP patients. De 
novo NP caused severe pain which may not easily be handled. Those study findings 
highlight that timely diagnosis and management of NP are required in patients 
with lumbar spine surgery.
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objeCtives: The Pain Assessment for Lower Back Symptoms (PAL-S) is a Patient 
Reported Outcome (PRO) instrument being developed to assess the key symptoms 
of chronic low back pain (cLBP). Qualitative development included both concept 
elicitation and cognitive interviews. As part of the ongoing development of the 
instrument, we further evaluated and refined the PAL-S using a mixed methods 
approach. Methods: Adults self-reporting a clinical diagnosis of cLBP were 
recruited from an existing US-based commercial survey panel to participate in 
a pilot quantitative study. Qualifying participants completed a web-based survey 
consisting of the 14-item PAL-S and items assessing clinical, treatment, and demo-
graphic characteristics. Study data was analyzed to assess item- and scale-level 
performance of the PAL-S using Rasch Measurement Theory analyses. Following 
analysis and modification, two waves of cognitive interviews were conducted to 
evaluate respondent understanding of the revised PAL-S. Results: The dataset 
included 598 respondents (mean age: 55.5±12.6; 67.9% female; 88.0% white; and 
54.0% married) who had cLBP for mean of 15.2±11.5 years. The Rasch analyses item 
threshold maps showed only two items having ordered thresholds, suggesting that 
respondents experienced increased difficulty distinguishing between options at 
the lower levels of the 0-10 scale. Simulations collapsing the responses to a best-
fit 4-point response scale resulted in improved ordering of thresholds, suggesting 
a more optimal response option structure. Based on these findings, the numeric 
response scale of the PAL-S items was replaced with a 4-point verbal rating scale 
incorporating response choices such as not at all, slight, moderate, and severe. Findings 
from eight cognitive interviews confirmed patient comprehension and relevance 
of the revised instrument. ConClusions: The mixed-methods approach proved 
valuable to the ongoing development of the PAL-S, as Rasch analyses identified 
a need for refinement of the response scale. The measurement properties of the 
revised PAL-S will be evaluated in additional web-based and clinic-based quantita-
tive studies.
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objeCtives: The Pain Assessment for Lower Back-Impacts (PAL-I) is a patient-
reported outcome (PRO) instrument being developed to assess key impacts, e. 
g. walking, sitting, standing, etc. associated with chronic low back pain (cLBP). 
Following a mixed methods approach, the PAL-I development included qualitative 
work (both concept elicitation and cognitive interviews) and now a quantitative 
“pilot study” evaluation for further content validity. Methods: Adults self-report-
ing a clinical diagnosis of cLBP were recruited from a US-based commercial survey 
panel. Qualifying participants completed a web-based survey consisting of the 
13-item PAL-I and items assessing clinical, treatment, and demographic character-
istics. Study data was analyzed to assess item- and scale-level performance of the 
PAL-I using Rasch Measurement Theory analyses. Following analysis and modifica-
tion, cognitive interviews were conducted to evaluate patient understanding of the 
revised PAL-I. Results: The 598 subjects in the pilot study reported having cLBP 
(mean of 6.1 on 11-point numerical rating scale, 0= no pain). Subjects experienced 
cLBP for 0.3 to 66 years (mean 15.2, SD 11.5), were 55.5 years old (SD 12.6), 67.9% 
female, 88.0% white and 54.0% married. The Rasch item threshold map showed 
only 2 items having an ordered threshold identifying problems with the response 
categories. Category probability curves indicated subjects had “difficulty” endorsing 
items specifically in relation to the extreme options. Based on these findings, four 
items were removed and the response options were modified for the remaining 
items (from 6-point scale 4-point: Not at all limited, Limited a little, Limited a lot, Did 
not do). Comprehension of the revised instrument was evaluated and confirmed 
